The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Strong topline growth driven by solid performance across key brands.
Subscribe To Our Newsletter & Stay Updated
